To further utilize the fact that the transcripts of S100A8 and S100A9 are upregulated in GBM and specifically mesenchymal subtype of GBM we established their diagnostic capability to discriminate GBM from control brain and grade III gliomas and also mesenchymal subgroup from other subgroups within GBM. This evidence concerns the gene S100A8 and central nervous system cancer.